Inotek
From Wikipedia, the free encyclopedia
 |
This article is orphaned as few or no other articles link to it. Please help introduce links in articles on related topics. (October 2006) |
Inotek Pharmaceuticals Corporation is a development-stage pharmaceutical company that previously entered patients into phase II trial for its compound IND-001, for the prevention of cardiac necrosis. INO-1001 is a potent inhibitor of PARP.
It is based in Beverly, Massachusetts.
This United States corporation or company article is a stub. You can help Wikipedia by expanding it.
